Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients
Microbiology Spectrum · 2023
DOI: 10.1128/spectrum.04437-22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2023. Verfasst von Michael Marner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Bioresources, Giessen, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas Infections. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) represents an ever increasing threat to the health care system. Even recently licensed drugs are often not efficient for the treatment of infections caused by Gram-negative bacteria, like Pseudomonas aeruginosa , a causative agent of lung infections. To address this unmet medical need, innovative antibiotics, which possess a new mode of action, need to be developed. Here, the antibiogram of clinical isolates derived from cystic fibrosis patients was generated and new bicyclic heptapeptides, which inhibit the outer membrane protein BamA, exhibited strong activity, also against multidrug-resistant isolates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Bioresources, Giessen, Germany.
- Justus-Liebig-University of Giessen, Giessen, Germany.
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.
- Institute for Medical Information Processing, Biometry, and Epidemiology - IBE, LMU Munich, Munich, Germany.
- Pettenkofer School of Public Health, Munich, Germany.
- German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Giessen, Germany.
ORCID-Profile: Michael Marner, Laura Kolberg, Till F Schäberle, Ulrich von Both
Förderung
- Bundesministerium für Bildung und Forschung
Zitieren
APA
Marner, M., Kolberg, L., Horst, J., Böhringer, N., Hübner, J., Kresna, I. D. M., Liu, Y., Mettal, U., Wang, L., Meyer-Bühn, M., Mihajlovic, S., Kappler, M., Schäberle, T. F., & von Both, U. (2023). Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Microbiology Spectrum. https://doi.org/10.1128/spectrum.04437-22
Vancouver
Marner M, Kolberg L, Horst J, Böhringer N, Hübner J, Kresna IDM, et al. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients. Microbiology Spectrum. 2023. doi:10.1128/spectrum.04437-22
BibTeX
@article{Marner2023,
author = {Marner, Michael and Kolberg, Laura and Horst, Julia and Böhringer, Nils and Hübner, Johannes and Kresna, I Dewa M and Liu, Yang and Mettal, Ute and Wang, Lei and Meyer-Bühn, Melanie and Mihajlovic, Sanja and Kappler, Matthias and Schäberle, Till F and von Both, Ulrich},
title = {Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients},
journal = {Microbiology Spectrum},
year = {2023},
doi = {10.1128/spectrum.04437-22}
}
EUVIMED